Research programme: anticancer fusion toxins - Viscum AG
Alternative Names: Anticancer fusion toxins research programme - Viscum AGLatest Information Update: 24 Apr 2007
At a glance
- Originator VISCUM AG
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer